Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.84)
# 3,250
Out of 5,182 analysts
117
Total ratings
36.36%
Success rate
0.54%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $11 | $7.21 | +52.57% | 6 | Apr 22, 2026 | |
| ACHV Achieve Life Sciences | Reiterates: Buy | $12 | $3.96 | +203.03% | 4 | Apr 16, 2026 | |
| SINT Sintx Technologies | Initiates: Buy | $10 | $2.35 | +325.53% | 1 | Apr 13, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $0.89 | +1,136.09% | 5 | Mar 27, 2026 | |
| DERM Journey Medical | Reiterates: Buy | $13 | $5.26 | +147.15% | 3 | Mar 26, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $60 | $32.78 | +83.04% | 9 | Mar 20, 2026 | |
| PTHS Pelthos Therapeutics | Reiterates: Buy | $60 | $24.77 | +142.23% | 2 | Mar 19, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $8.12 | +257.14% | 3 | Mar 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $14.27 | +47.16% | 4 | Mar 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $6.12 | +63.40% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $8 | $2.63 | +204.18% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.58 | +183.84% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.40 | +542.86% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $13.26 | +50.89% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $13 | $7.82 | +66.24% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.19 | +404.20% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $14.74 | +171.37% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.86 | +330.11% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.14 | +601.75% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.49 | +571.14% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $79.60 | +52.01% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.49 | +227.87% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.45 | +185.71% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.81 | +165.04% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.85 | +491.23% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.56 | +12,720.51% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.03 | +99.25% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $6.88 | +6,513.37% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $18.93 | +211.67% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $201.22 | -10.55% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.34 | +9,301.71% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $33.73 | -5.13% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.03 | +2,135,822.33% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.60 | +3,181.25% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $9.59 | +421.38% | 1 | Jul 12, 2018 |
Eupraxia Pharmaceuticals
Apr 22, 2026
Reiterates: Buy
Price Target: $11
Current: $7.21
Upside: +52.57%
Achieve Life Sciences
Apr 16, 2026
Reiterates: Buy
Price Target: $12
Current: $3.96
Upside: +203.03%
Sintx Technologies
Apr 13, 2026
Initiates: Buy
Price Target: $10
Current: $2.35
Upside: +325.53%
Rani Therapeutics Holdings
Mar 27, 2026
Reiterates: Buy
Price Target: $11
Current: $0.89
Upside: +1,136.09%
Journey Medical
Mar 26, 2026
Reiterates: Buy
Price Target: $13
Current: $5.26
Upside: +147.15%
Collegium Pharmaceutical
Mar 20, 2026
Reiterates: Buy
Price Target: $60
Current: $32.78
Upside: +83.04%
Pelthos Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $60
Current: $24.77
Upside: +142.23%
Sagimet Biosciences
Mar 11, 2026
Reiterates: Buy
Price Target: $29
Current: $8.12
Upside: +257.14%
Trevi Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $21
Current: $14.27
Upside: +47.16%
Xeris Biopharma Holdings
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $6.12
Upside: +63.40%
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $2.63
Upside: +204.18%
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.58
Upside: +183.84%
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.40
Upside: +542.86%
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $13.26
Upside: +50.89%
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.82
Upside: +66.24%
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.19
Upside: +404.20%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $14.74
Upside: +171.37%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.86
Upside: +330.11%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.14
Upside: +601.75%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.49
Upside: +571.14%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $79.60
Upside: +52.01%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $5.49
Upside: +227.87%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.45
Upside: +185.71%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.81
Upside: +165.04%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.85
Upside: +491.23%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.56
Upside: +12,720.51%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.03
Upside: +99.25%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $6.88
Upside: +6,513.37%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $18.93
Upside: +211.67%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $201.22
Upside: -10.55%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.34
Upside: +9,301.71%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $33.73
Upside: -5.13%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.03
Upside: +2,135,822.33%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.60
Upside: +3,181.25%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $9.59
Upside: +421.38%